Table 3.
Chemotherapy characteristics.
| Whole set of patients, n (%) | 593 (100) |
|---|---|
| Concurrent chemotherapy | |
| Number of patients, n (%) | 409 (69) |
| Drug, n (%) | |
| 5FU (oral or intravenous) | 331 (55.8) |
| FOLFOX | 60 (10) |
| Xelox | 11 (1.9) |
| Other | 7 (1.2) |
| Chemoradiotherapy setting, n (%) | |
| Pre-operative | 356 (60) |
| Post-operative | 40 (6.7) |
| Exclusive | 13 (2.3) |
| Sequential Chemotherapy | |
| Number of patients, n (%) | 5 (0.8) |
| Drug | |
| FOLFOX | 3 (0.5) |
| 5FU (oral or intravenous) | 2 (0.3) |
| Chemoradiotherapy setting | |
| Pre-operative | 0 |
| Post-operative | 5 (0.8) |
| Exclusive | 0 |
Q1: first interquartile, Q3: third interquartile.